Clinical Trial ProgressOnKure's molecule OKI-219 appears to have best-in-class tolerability, observing only Grade 1 TRAEs even at the highest dose and no discontinuations for safety.
Financial StabilityCash and cash equivalents were reported at $96.7 mn, which the company expects to provide a runway into 4Q26.
Pipeline DevelopmentOnKure will be announcing their pan-PI3Kα inhibitor and potential IND, indicating future growth prospects and development.